USES SKYRIZI is a prescription medicine used to treat adults with: moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV …

Jun 18, 2024 · The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) …

Nov 11, 2025 · Skyrizi (risankizumab) is an injection used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. Includes indications, doses, interactions, side effects and more.

Jul 23, 2024 · As a treatment for ulcerative colitis, Skyrizi works by fighting the inflammation that can lead to symptoms of the disease.

Jun 20, 2024 · The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as a treatment for people with moderately to severely active ulcerative colitis. The medication works by blocking the …

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This approval …

SKYRIZI® is indicated for the treatment of moderately to severely active ulcerative colitis in adults. See Important Safety and Prescribing Information.

Jun 2, 2025 · As gastroenterologists navigate the unmet needs of refractory ulcerative colitis, the FDA approval of risankizumab for ulcerative colitis marks a watershed moment, introducing the first IL-23 …

1 day ago · Effective 1/1/24 09/11/2024 – Reviewed and updated for September P&T. Added criteria for ulcerative colitis. Updated approval length for Skyrizi IV to 8 weeks.

Jun 21, 2024 · The FDA has approved Skyrizi (risankizumab-rzaa) for the treatment of moderately to severely active ulcerative colitis in adults.